Memphasys (FRA:IG7) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 24, 2026)


What is Memphasys Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Memphasys's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

FRA:IG7 vs ABT, SYK, MDT: Margin of Safety % (DCF Earnings Based) Comparison

For the Medical Devices subindustry, Memphasys's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Memphasys Margin of Safety % (DCF Earnings Based) vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Memphasys's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Memphasys's Margin of Safety % (DCF Earnings Based) falls into.


Memphasys Business Description

Other Exchanges MEM:Australia
Address 34-36 Richmond Road, Level 1, Homebush West, Sydney, NSW, AUS, 2140
Memphasys Ltd is an Australian reproductive biotechnology company developing and commercializing novel reproduction and fertility solutions for humans and animals. The products in its development pipeline include a range of devices, media, and in vitro diagnostic solutions. The company is currently focused on the commercialisation of its patented Felix System, a novel bio-separation technology for assisted reproduction, designed to revolutionise sperm separation in assisted reproductive technology (ART) by providing a rapid, gentle, and automated process. The group has only one operating segment, being Reproductive Technologies, the assets and liabilities of which are located in Australia.